AbCellera Biologics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +84.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 9.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth B-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -46.3% | Better than 1% |
| Net income CAGR (3Y) | 691.9% | Better than 100% |
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 100.0% | Better than 99% |
| Operating margin | -270.5% | Better than 5% |
| Net margin | -194.9% | Better than 5% |
| Return on equity | -14.5% | Better than 17% |
| Return on invested capital | -15.2% | Better than 15% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -14.4% | Better than 41% |
| 6-month return | 86.3% | Better than 99% |
| 12-month return (ex latest month) | 236.8% | Better than 99% |
| Distance below 52-week high | 35.5% | Better than 34% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 11.3x | Better than 94% |
| Debt to assets | 10.6% | Better than 69% |
| Interest coverage | 60.1x | Better than 91% |
| Free cash flow / net income | 129.1% | Better than 57% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 88.9% | Better than 72% |
| Upside to average target | 99.5% | Better than 83% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 10.47
- Open
- 10.14
- Day range
- 9.58 - 10.26
- Avg price
- 9.86
- Volume
- 4.25M
- Turnover
- 41.88M
- Turnover ratei
- 1.89%
- Volume ratioi
- 1.63
- Amplitudei
- 6.50%
- 52-week rangei
- 2.75 - 15.02
Valuation
- P/Ei
- -19.78
- P/E (TTM)i
- -20.19
- P/Bi
- 2.98
- EPSi
- -0.49
- Book value / shi
- 3.25
- Net profit
- -160.04M
- Net assets
- 1.06B
Share structure
- Market cap
- 3.16B
- Float capi
- 2.17B
- Shares out
- 326.62M
- Float sharesi
- 224.45M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-12-11
35.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-24.73M net over the window
Short interest
- Shares short
- 29.02M
- % of floati
- 8.96%
- Days to coveri
- 8.49
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of AbCellera Biologics (ABCL)?
AbCellera Biologics last traded at 9.69. This page shows a periodic quote snapshot. Check the displayed quote time.
What is AbCellera Biologics's market cap?
About 3.16B.
What is the P/E ratio of AbCellera Biologics?
The trailing twelve-month P/E is -20.19. The Valuation tab shows it against the stock's own five-year range.
Does AbCellera Biologics pay a dividend?
AbCellera Biologics does not currently pay a regular dividend.
Is AbCellera Biologics a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 19.33, which implies 99.5% upside from the current price. This is not investment advice.
What is AbCellera Biologics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates AbCellera Biologics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.
AbCellera Biologics discussion 0 comments